KOMBINASI ATORVASTATIN DAN SUPLEMEN OMEGA-3 DALAM MEMPERBAIKI PROFIL LIPID PADA MENCIT (MUS MUSCULUS) MODEL DISLIPIDEMIA
DOI:
https://doi.org/10.31004/jkt.v4i4.15569Keywords:
atorvastatin, kolesterol, omega-3Abstract
Dislipidemia didefinisikan sebagai kelainan metabolisme lipid (lipoprotein, kolesterol total, dan trigliserida) dengan kadar yang melampaui batas normal. Di Indonesia, penelitian terdahulu yang relevan guna melihat efektivitas kombinasi atorvastatin dan omega-3 dalam terapi dislipidemia masih sangat terbatas dikarenakan adanya perancu pada penelitian yaitu berupa penyakit komorbid yang dapat mempengaruhi hasil. Penelitian ini bertujuan untuk membandingkan pengaruh pemberian monoterapi atorvastatin dan kombinasi dengan suplemen omega-3 terhadap profil lipid (TG, HDL, dan LDL) pada mencit (Mus musculus). Penelitian eksperimental ini menggunakan 10 ekor mencit putih jantan jenis ddy yang diinduksi kolesterol dan dibagi menjadi 2 kelompok secara acak. Perlakuan diberikan selama 1 bulan, lalu diambil sampel darah dan dicek profil lipidnya (HDL, LDL, dan TG). Hasil penelitian menunjukkan terdapat pebedaan bermakna pada kadar HDL dan LDL dengan sig. 0,000 < 0,05 dan nilai sig. pada TG 0,009 < 0,05 antar kelompok perlakuan. Penambahan suplemen omega-3 terbukti memiliki efek yang signifikan dalam meningkatkan kadar HDL, menurunkan kadar LDL dan TG.References
Abdel-Moneim, A., Mahmoud, B., & Mahmoud, R. (2015). The Benefecial Effects Of Fish Oil Supplementation On Hyperlipidemic And Hypothyroid Albino Rats. 8(4).
Barter, P., & Ginsberg, H. N. (2008). Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia. The American Journal of Cardiology, 102(8), 1040–1045. https://doi.org/10.1016/j.amjcard.2008.05.056
Bowen, K. J., Harris, W. S., & Kris-Etherton, P. M. (2016). Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? Current Treatment Options in Cardiovascular Medicine, 18(11), 69. https://doi.org/10.1007/s11936-016-0487-1
Choi, H. D., & Chae, S. M. (2018). Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia. Medicine, 97(50), e13593. https://doi.org/10.1097/MD.0000000000013593
Dizaye, K., & Jarjees, H. (2014). Effects of Omega-3 on Lipid Profile and Haematological Parameters in Hyperlipidemic Rats. Middle East Journal of Internal Medicine, 7(3), 34–40. https://doi.org/10.5742/MEIM.2014.92553
Eussen, S. R. B. M., Geleijnse, J. M., Giltay, E. J., Rompelberg, C. J. M., Klungel, O. H., & Kromhout, D. (2012). Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. European Heart Journal, 33(13), 1582–1588. https://doi.org/10.1093/eurheartj/ehr499
Jun, J. E., Jeong, I. K., Yu, J. M., Kim, S. R., Lee, I. K., Han, K. A., Choi, S. H., Kim, S. K., Park, H. K., Mok, J. O., Lee, Y. H., Kwon, H. S., Kim, S. H., Kang, H. C., Lee, S. A., Lee, C. B., Choi, K. M., Her, S. H., Shin, W. Y., … Lee, M. K. (2020). Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes & Metabolism Journal, 44(1), 78–90. https://doi.org/10.4093/dmj.2018.0265
Kemenkes RI. (2018). Hasil Utama Riskesdas 2018. Kementerian Kesehatan RI.
Kim, C. H., Han, K. A., Yu, J., Lee, S. H., Jeon, H. K., Kim, S. H., Kim, S. Y., Han, K. H., Won, K., Kim, D.-B., Lee, K.-J., Min, K., Byun, D. W., Lim, S.-W., Ahn, C. W., Kim, S., Hong, Y. J., Sung, J., Hur, S.-H., … Kim, H.-S. (2018). Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial. Clinical Therapeutics, 40(1), 83–94. https://doi.org/10.1016/j.clinthera.2017.11.007
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012). Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. Journal of Clinical Lipidology, 6(5), 413–426. https://doi.org/10.1016/j.jacl.2012.04.003
Ng, T. W. K., Ooi, E. M. M., Watts, G. F., Chan, D. C., & Barrett, P. H. R. (2014). Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men. Diabetes, Obesity & Metabolism, 16(6), 519–526. https://doi.org/10.1111/dom.12243
PERKI. (2017). Pandan Tatalaksana Dislipidemia 2017. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. https://spesialis1.kardio.fk.unair.ac.id/wp-content/uploads/2021/02/PERKI-DYSLIPIDEMIA-2017.pdf
Sari, D. P., Susilo, I., & Khotib, J. (2017). THE MECHANISM OF ALPHA LIPOIC ACID ON REDUCING THE MDA LEVEL AND MCP-1 EXPRESSION IN ENDOTHELIAL DYSFUNCTION OF HYPERCHOLESTEROLEMIA RAT (Rattus norvegicus) MODEL. Folia Medica Indonesiana, 52(3), 154. https://doi.org/10.20473/fmi.v52i3.5444
Son, J. W., Kim, C.-H., Nam, M. S., Park, I. B., & Yoo, S. J. (2019). Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: A Randomized Controlled Trial. Journal of Lipid and Atherosclerosis, 8(2), 221–231. https://doi.org/10.12997/jla.2019.8.2.221
Ugbaja, R. N., Owoeye, F. D., DosumuA, O. A., Onunkwor, B. O., Rotimi, S. O., Ademuyiwa, O., Fayemi, A. E., Oginni, F. F., & Ogundana, D. A. (2013). Beneficial effects of omega-3 fatty acid on dyslipidemia in organs of alloxan-induced diabetic rats.
Woo, J. S., Hong, S. J., Cha, D. H., Kim, K. S., Kim, M. H., Lee, J.-W., Jeong, M. H., Jeong, J.-O., Lee, J.-H., Jeon, D. S., Cho, E. J., Kim, S. K., Kwan, J., Park, C. G., Lee, H. Y., Hong, T. J., Shin, J., Youn, H. J., Jeon, D. W., … Kim, C. J. (2021). Comparison of the Efficacy and Safety of Atorvastatin 40 mg/?-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study. Clinical Therapeutics, 43(8), 1419–1430. https://doi.org/10.1016/j.clinthera.2021.07.001
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., & Japan EPA lipid intervention study (JELIS) Investigators. (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet (London, England), 369(9567), 1090–1098. https://doi.org/10.1016/S0140-6736(07)60527-3
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Asri Wido Mukti, Dewi Perwito Sari, Solichatin Solichatin
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
